Aura Biosciences, Inc. (AURA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$48.07M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$34.87M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$27.91M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$28.61M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$48.07M | (m) | (m) | (m) | $21.00K* | -$32.50M* | (m) | $30.75M | (m) | $29.00K |
| 2026-03-31 | Reported | (m) | -$34.87M | (m) | (m) | (m) | $102.00K | -$29.89M | (m) | $27.96M | (m) | $11.00K |
| 2025-09-30 | Reported | (m) | -$27.91M | (m) | (m) | (m) | $45.00K* | -$20.14M* | (m) | $22.18M | (m) | $26.00K |
| 2025-06-30 | Reported | (m) | -$28.61M | (m) | (m) | (m) | $39.00K* | -$20.77M* | (m) | $22.88M | (m) | $48.00K |
| 2025-03-31 | Reported | (m) | -$29.04M | (m) | (m) | (m) | $187.00K | -$23.36M | (m) | $23.34M | (m) | $18.00K |
| 2024-09-30 | Reported | (m) | -$23.23M | (m) | (m) | (m) | $341.00K* | -$15.27M* | (m) | $17.04M | (m) | $43.00K |
| 2024-06-30 | Reported | (m) | -$22.76M | (m) | (m) | (m) | $525.00K* | -$16.13M* | (m) | $16.88M | (m) | $0.00* |
| 2024-03-31 | Reported | (m) | -$22.31M | (m) | (m) | (m) | $88.00K | -$24.45M | (m) | $17.05M | (m) | $46.00K |
| 2023-09-30 | Reported | (m) | -$20.49M | (m) | (m) | (m) | $90.00K* | -$15.40M* | (m) | $15.43M | (m) | $0.00* |
| 2023-06-30 | Reported | (m) | -$20.28M | (m) | (m) | (m) | $193.00K* | -$14.64M* | (m) | $15.12M | (m) | $0.00* |
| 2023-03-31 | Reported | (m) | -$19.44M | (m) | (m) | (m) | $109.00K | -$16.41M | (m) | $14.40M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$16.05M | (m) | (m) | (m) | $63.00K* | -$10.76M* | (m) | $11.29M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$13.82M | (m) | (m) | (m) | $74.00K* | -$10.63M* | (m) | $9.51M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$12.81M | (m) | (m) | (m) | $599.00K | -$15.20M | (m) | $8.28M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$8.89M | (m) | (m) | (m) | $573.00K* | -$8.69M* | (m) | $6.37M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$8.80M | (m) | (m) | (m) | $662.00K* | -$6.50M* | (m) | $6.63M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$5.93M | (m) | (m) | (m) | $71.00K | -$5.14M | (m) | $4.18M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$3.63M | (m) | (m) | (m) | (m) | (m) | (m) | $2.85M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$112.79M | (m) | (m) | (m) | $447.00K | -$84.74M | (m) | $90.30M | (m) | $108.00K |
| 2024-12-31 | Reported | (m) | -$96.12M | (m) | (m) | (m) | $1.25M | -$79.81M | (m) | $73.30M | (m) | $112.00K |
| 2023-12-31 | Reported | (m) | -$84.99M | (m) | (m) | (m) | $709.00K | -$63.85M | (m) | $65.23M | (m) | $137.00K |
| 2022-12-31 | Reported | (m) | -$60.30M | (m) | (m) | (m) | $1.09M | -$54.60M | (m) | $42.24M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$35.25M | (m) | (m) | (m) | $2.13M | -$32.41M | (m) | $25.16M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$22.21M | (m) | (m) | (m) | $771.00K | -$24.32M | (m) | $18.04M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |